Answers are grounded in this paper and cite their sources.
Central serous retinopathy (CSR) is a lesser-established ocular toxicity associated with BRAF/MEK inhibitors, a targeted treatment used in BRAF-mutated melanoma. This case study outlines a patient with metastatic cutaneous melanoma, who developed bilateral multifocal CSR secondary to dabrafenib and trametinib, two commonly used BRAF/MEK inhibitors. This report aims to improve the understanding of CSR as an adverse effect of BRAF/MEK inhibitors, including the potential for sight threatening ocular toxicity. It also aims to emphasise the importance of multi-specialty management to manage such toxicity while upholding delivery of cancer treatment in the best interests of the patient. In this case, the BRAF/MEK inhibitors were re-commenced at half dose and the CSR did not further progress, demonstrating an alternative option to halting treatment or switching to second-line therapy. Ultimately, a risk versus benefit approach is required, with decision making involving the multi-disciplinary team centred around an informed patient.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: